Valeo Pharma
  • About Us
    • Overview
    • Board of Directors
    • Executive Team
  • Product Portfolio
    • Respiratory / Allergy
    • Ophthalmology
    • Specialty Products
    • Neurology
    • Oncology
  • Partnering
  • Investors
    • Investor Relations
    • Stock information
    • Corporate Presentation
    • Financial Reports
    • Newsroom
    • Webcasts / Events
    • SEDAR documents
  • Careers
  • Contact
  • Français
Select Page
VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023 

VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023 

by Fred Dumais | May 25, 2023 | News Release

Q2-23 revenues to exceed $13.5 million  Q2-23 adjusted EBITDA loss to decrease below $2.0 million  Q2-23 operating expenses to remain in line with prior quarters  ENERZAIR® and ATECTURA® quarterly revenues grow 270% over prior year  MONTREAL, QUEBEC , May 25, 2023 –...
VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS

VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS

by Fred Dumais | Apr 28, 2023 | News Release

MONTREAL, QUEBEC , April 28, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced the results of the proposals submitted to shareholders at its annual meeting of shareholders held on...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

by Fred Dumais | Apr 19, 2023 | News Release

MONTREAL, QUEBEC , April 19, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that Steve Saviuk, Valeo’s Chief Executive Officer, will present a corporate overview and provide a...
VALEO PHARMA TO PRESENT AT THE 2023 BLOOM BURTON & CO HEALTHCARE INVESTOR CONFERENCE  

VALEO PHARMA REPORTS RECORD QUARTERLY REVENUES FOR THE FIRST QUARTER 2023

by Fred Dumais | Mar 15, 2023 | News Release

• Fifth consecutive quarter of revenue growth at $13.2 million in Q1-23, up 210% over Q1-22 • Fifth consecutive quarter of adjusted gross profit increase at $4.2 million, up 178% over Q1-22 • Fifth consecutive quarter of adjusted EBITDA loss reduction at $2.2 million,...
VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     

VALEO PHARMA TO HOST FIRST QUARTER 2023 RESULTS CONFERENCE CALL / WEBCAST     

by Fred Dumais | Mar 9, 2023 | News Release

MONTREAL, QUEBEC , March 9, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the first quarter ended January 31, 2023...
VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC

VALEO PHARMA OBTAINS PUBLIC REIMBURSEMENT FOR ONSTRYV® IN QUEBEC

by Fred Dumais | Feb 7, 2023 | News Release

Quebec public reimbursement coverage to facilitate and expand medication access for Parkinson’s patients in Quebec MONTREAL, QUEBEC , February 7, 2023 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company,...
« Older Entries

Recent News

  • VALEO PHARMA ANTICIPE DES REVENUS RECORDS POUR LE DEUXIÈME TRIMESTRE DE 2023  May 25, 2023
  • VALEO PHARMA PROVIDING GUIDANCE OF RECORD REVENUES FOR THE SECOND QUARTER 2023  May 25, 2023
  • VALEO PHARMA ANNONCE LES RÉSULTATS DE L’ASSEMBLÉE ANNUELLE DES ACTIONNAIRES ET LES NOMINATIONS AUX COMITÉS April 28, 2023
  • VALEO PHARMA ANNOUNCES RESULTS OF ANNUAL MEETING OF SHAREHOLDERS AND COMMITTEE APPOINTMENTS April 28, 2023

Stay in the loop

I consent to receive news, updates and special offers from Valeo Pharma and it’s affiliates.

Contact us

1-855-694-0151
[email protected]
16667 Hymus Blvd.
Kirkland, QC H9H 4R9

  • About Us
  • Board of Directors
  • Management Team
  • Careers
  • Our Products
  • Business Development
  • Investors Overview
  • Newsroom
  • Stock Information
  • Financial Reports
  • Contact Us
  • Français

© 2022 Valeo Pharma. All rights reserved.

Speak to a professional

I want to speak to:

3 + 13 =